$8.01
arrow_drop_up1.13%Key Stats | |
---|---|
Open | $7.92 |
Prev. Close | $7.91 |
EPS | 0.27 |
Dividend | Non-Dividend |
Next Earnings Date | - |
Dividend Yield % | - |
LOW | HIGH | |
---|---|---|
Day Range | 7.70 | 8.08 |
52 Week Range | 5.71 | 11.72 |
Ratios | |
---|---|
EPS | 0.27 |
Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.
Period: Next 12 Months
•Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.
Tau Inhibitors Clinical Trial Pipeline Analysis Demonstrates 25+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight
Gene Therapy Market Size to Reach USD 54.39 Billion By 2032 with CAGR of 23.12%, Boosted by Rising Genetic Disorders and Advances in CRISPR Technology
Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Voyager Therapeutics to Present at Multiple Virtual Investor Conferences
Voyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer
Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s Disease